Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corp, has reported a series of significant stock transactions in a recent filing with the SEC. On October 22, 2026, Rothblatt executed multiple trades involving the company's common stock, highlighting her active role in managing her ownership stake.
United Therapeutics, a company focused on pharmaceutical preparations, is known for its innovative approaches to treating chronic and life-threatening conditions. The recent transactions by Rothblatt underscore her commitment to the company and its mission.
Details of the Transactions
According to the SEC filing, Rothblatt acquired 9,500 shares of United Therapeutics at a price of $117.76 per share. Additionally, she disposed of several blocks of shares, including 74 shares at $562.97 each, 110 shares at $563.98, and 160 shares at $565.09. The filing indicates that Rothblatt's ownership in the company remains substantial, with 333,943 shares held following these transactions.
Background on United Therapeutics
United Therapeutics Corp, incorporated in Delaware, is recognized under the SIC code for Pharmaceutical Preparations. The company is headquartered in Silver Spring, Maryland, and has been a leader in developing unique therapies for patients with serious health conditions. With a fiscal year ending on December 31, United Therapeutics continues to innovate in the pharmaceutical space.
Impact of Rothblatt's Transactions
Rothblatt's transactions may have implications for the company's governance and investor relations. As a key figure in the pharmaceutical industry, her actions could influence investor confidence and market perceptions of United Therapeutics. The transparency of these transactions is essential for maintaining trust among shareholders and stakeholders.
What's Next?
The filing does not specify any future actions or upcoming events related to these transactions. However, continued monitoring of Rothblatt's stock activity may provide insights into her strategic decisions and the company's direction.
Source: SEC Filing Accession Number 0001106578-26-000170